Immunohistochemical results of five patients with UTROSCT
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
| CK | 1+ | 1+ | 1+ | 2+ | 2+ |
| WT-1 | – | – | 3+ | – | 2+ |
| CD99 | 2+ | 2+ | 2+ | 2+ | – |
| CR | 2+ | 2+ | 2+ | – | 2+ |
| α-Inhibin | – | 1+ | – | – | – |
| SF-1 | – | 2+ | 2+ | – | 2+ |
| EMA | – | – | – | – | – |
| Desmin | – | 2+ | – | 2+ | 1+ |
| SMA | 2+ | 1+ | 1+ | 3+ | – |
| h-Caldesmon | 2+ | 2+ | 2+ | 2+ | 1+ |
| BCL-2 | 3+ | 3+ | 3+ | 3+ | 3+ |
| ER | 1+ | 1+ | 2+ | 3+ | 2+ |
| PR | 3+ | 3+ | 3+ | 3+ | 2+ |
| CD10 | 1+ | 1+ | 1+ | 1+ | – |
‘–’ indicates negativity; ‘1+’ denotes weak or focal positivity, with a number of positive cells <25%; ‘2+’ indicates moderate positivity, with a number of positive cells of 25%–75%; ‘3+’ denotes diffuse strong positivity, with a number of positive cells >75%.
BCL-2, B cell lypmphoma-2; CD10, cluster of differentiation 10; CD99, cluster of differentiation 99; CK, cytokeratin; EMA, epithelial membrane antigen; ER, oestrogen receptor; PR, progesterone receptor; SF-1, steroidogenic factor-1; SMA, smooth muscle actin; UTROSCT, tumours resembling ovarian sex cord tumour; WT-1, Wilms' tumour 1.